GlassScriptPhysician profile
Kyle A Anderson
NPI 1720221617
$23,242.91
in general payments reported to CMS, 2019-2025
45 companies · $4,355 in 2025
The $4,355 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,716 · 2020: $2,270 · 2021: $3,080 · 2022: $2,819 · 2023: $3,652 · 2024: $4,350 · 2025: $4,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $450 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,898.71 |
| Consulting Fee | $450.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,756.00 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $3,172.19 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,406.17 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $1,394.36 | 2019-2025 | Winlevi, Blu-U, Ilumya |
| Mayne Pharma Commercial LLC | $1,349.18 | 2019-2025 | |
| Leo Pharma INC. | $1,315.99 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $1,297.89 | 2019-2025 | |
| Ucb, INC. | $1,149.64 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $993.77 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $948.13 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $900.11 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $677.06 | 2019-2025 | Nemluvio, Oracea |
| Dermavant Sciences, INC. | $595.77 | 2023-2024 | Vtama |
| Amgen INC. | $542.20 | 2020-2025 | Otezla, Otezla |
| Almirall LLC | $540.12 | 2019-2025 | Seysara |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.